|
NUDT3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.90040205794162E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.15559833608381E-11 |
| Normal-vs-Stage2 |
1.221480E-04 |
| Normal-vs-Stage3 |
2.99169999995463E-07 |
| Normal-vs-Stage4 |
4.03539999971336E-07 |
| Stage1-vs-Stage2 |
3.863000E-01 |
| Stage1-vs-Stage3 |
7.986000E-02 |
| Stage1-vs-Stage4 |
4.892200E-01 |
| Stage2-vs-Stage3 |
7.003600E-01 |
| Stage2-vs-Stage4 |
7.835200E-01 |
| Stage3-vs-Stage4 |
4.320400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.10429501285626E-11 |
| Normal-vs-AfricanAmerican |
1.242490E-03 |
| Normal-vs-Asian |
3.65669999835561E-08 |
| Caucasian-vs-AfricanAmerican |
8.520600E-01 |
| Caucasian-vs-Asian |
8.989000E-01 |
| AfricanAmerican-vs-Asian |
8.941400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.65059999999162E-05 |
| Normal-vs-Female |
1.99673610978834E-12 |
| Male-vs-Female |
2.558400E-03 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.8587020811367E-11 |
| Normal-vs-Age(41-60Yrs) |
2.10799999678102E-09 |
| Normal-vs-Age(61-80Yrs) |
5.59509999999985E-05 |
| Normal-vs-Age(81-100Yrs) |
2.260000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.356000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.016400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.289900E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.161600E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.550230E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.978200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.066000E-01 |
| Classical-VS-Follicular |
1.416470E-02 |
| Classical-VS-Other |
2.846000E-01 |
| Classical-VS-Normal |
3.51396689524108E-12 |
| Tall-VS-Follicular |
6.754500E-02 |
| Tall-VS-Other |
3.020600E-01 |
| Tall-VS-Normal |
3.41479999999006E-06 |
| Follicular-VS-Other |
2.030400E-01 |
| Follicular-VS-Normal |
3.952500E-04 |
| Other-VS-Normal |
1.151190E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.33469999497038E-08 |
| Normal-vs-N1 |
1.040000E-04 |
| N0-vs-N1 |
4.091600E-01 |
|
|
